Detalhe da pesquisa
1.
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis with an all-oral 9-month regimen containing linezolid or ethionamide in South Africa: A retrospective cohort study.
Clin Infect Dis
; 2024 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38525535
2.
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Clin Infect Dis
; 78(3): 730-741, 2024 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37874021
3.
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.
Clin Infect Dis
; 76(9): 1658-1670fc, 2023 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36609692
4.
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
Eur Respir J
; 57(6)2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33243847
5.
Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis.
Emerg Infect Dis
; 26(3)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31922953
6.
Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.
Eur Respir J
; 60(2)2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35777762
7.
Practices of therapeutic drug monitoring in tuberculosis: an international survey.
Eur Respir J
; 59(4)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086830
8.
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization.
Eur Respir J
; 57(4)2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33833074
9.
World Health Organization treatment outcome definitions for tuberculosis: 2021 update.
Eur Respir J
; 58(2)2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34413124
10.
WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence.
Eur Respir J
; 55(3)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32139588
11.
Multidrug-resistant tuberculosis around the world: what progress has been made?
Eur Respir J
; 45(1): 150-60, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25261327
12.
Multidrug-resistant tuberculosis.
Nat Rev Dis Primers
; 10(1): 22, 2024 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38523140
13.
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
Eur Respir J
; 51(3)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567719
14.
Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF.
Eur Respir J
; 42(1): 252-71, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23180585
15.
Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysis.
EClinicalMedicine
; 58: 101938, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37090436
16.
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis.
Nat Commun
; 14(1): 6182, 2023 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37794037
17.
Drug-Resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007.
Emerg Infect Dis
; 17(10): 1913-6, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22000370
18.
WHO's new end TB strategy.
Lancet
; 385(9979): 1799-1801, 2015 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25814376
19.
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.
Drug Des Devel Ther
; 15: 2815-2830, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34234413
20.
Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscape.
Int J Infect Dis
; 108: 557-567, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34139370